Skip to main content
In stock|Targeted Therapy

Brigimadlin

Oncology TypeBoth (Solid & Hematologic)
Drug Class / MechanismMDM2 Inhibitor
No Image
Description

Brigimadlin is classified as a MDM2 Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy
Oncology TypeBoth (Solid & Hematologic)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3